β-lactam Resistance in <i>Pseudomonas aeruginosa</i>: Current Status, Future Prospects
<i>Pseudomonas aeruginosa</i> is a major opportunistic pathogen, causing a wide range of acute and chronic infections. β-lactam antibiotics including penicillins, carbapenems, monobactams, and cephalosporins play a key role in the treatment of <i>P. aeruginosa</i> infections....
Main Authors: | Karl A. Glen, Iain L. Lamont |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Pathogens |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-0817/10/12/1638 |
Similar Items
-
Prolonged versus intermittent β-lactam infusion in sepsis: a systematic review and meta-analysis of randomized controlled trials
by: Yang Zhao, et al.
Published: (2024-02-01) -
Could β-Lactam Antibiotics Block Humoral Immunity?
by: Cléa Melenotte, et al.
Published: (2021-09-01) -
Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis
by: Huai Qin Cang, et al.
Published: (2023-10-01) -
New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams
by: Juan C. Vázquez-Ucha, et al.
Published: (2020-12-01) -
Prevalence of IMP and VIM Metallo-Beta-Lactamases in Pseudomonas aeruginosa Isolates from Clinical and Environmental Specimens in Intensive Care Units (ICUs) of Rasht Hospitals, Iran
by: Matin Saberi, et al.
Published: (2015-07-01)